Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SONIBEC
2024-516797-29-00Phase 2Authorised
- Sponsor
- GONO Foundation
- Start
- Oct 2024
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sonidegib in basal cell carcinoma (BCC), sponsored by GONO Foundation. Primary endpoint: Proportion of patients maintaining the tailored treatment with sonidegib 12 months after enrolment into the study. Planned start Oct 2024; status: authorised.
02
Drugs
sonidegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2024-516797-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516797-29-00.